SCHEMBL122295

SCHEMBL122295

CC(N)(Cc1ccccc1)C(=O)O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BLM P54132 2/20 0.72
SMN1; SMN2 Q16637 1/20 0.64
HIF1A Q16665 1/20 0.64
CYP3A4 P08684 3/20 0.61
CYP1A2 P05177 3/20 0.61
ALDH1A1 P00352 3/20 0.61
RECQL P46063 2/20 0.61
KDM4E B2RXH2 1/20 0.61
MEN1 O00255 1/20 0.61
USP2 O75604 1/20 0.61
EGFR P00533 1/20 0.61
FYN P06241 1/20 0.61
POLB P06746 1/20 0.61
GAA P10253 1/20 0.61
MAPT P10636 1/20 0.61
HPGD P15428 1/20 0.61
ALOX15 P16050 1/20 0.61
APEX1 P27695 1/20 0.61
ADRA1A P35348 1/20 0.61
PTGS2 P35354 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL122296 1.00 BLM (0.72) BLMSMN1; SMN2HIF1ACYP3A4CYP1A2
SCHEMBL202327 1.00 BLM (0.72) BLMSMN1; SMN2HIF1ACYP3A4CYP1A2
Water SCHEMBL11327784 0.98 BLM (0.70) BLMSMN1; SMN2HIF1ACYP3A4CYP1A2
Hydrochloric Acid SCHEMBL22462476 0.98 BLM (0.70) BLMSMN1; SMN2HIF1ACYP3A4CYP1A2
Water SCHEMBL11329765 0.98 BLM (0.70) BLMSMN1; SMN2HIF1ACYP3A4CYP1A2
Hydrochloric Acid SCHEMBL4331797 0.98 BLM (0.70) BLMSMN1; SMN2HIF1ACYP3A4CYP1A2
SCHEMBL6532058 0.89 BLM (0.69) BLMSMN1; SMN2HIF1ACYP3A4CYP1A2
SCHEMBL14037306 0.89 BLM (0.69) BLMSMN1; SMN2HIF1ACYP3A4CYP1A2
SCHEMBL407787 0.86 SLC6A2 (0.57) BLMSMN1; SMN2HIF1ACYP3A4CYP1A2
SCHEMBL10078943 0.86 SLC6A2 (0.57) BLMSMN1; SMN2HIF1ACYP3A4CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1291 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12521455-B2 Kisspeptin receptor (KISS1R) targeted therapeutics and uses thereof RADIONETICS ONCOLOGY, INC. (US) 2026-01-13 US claimed
US-20250312499-A1 KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF RADIONETICS ONCOLOGY, INC. 2025-10-09 US claimed
CN-120157771-A Incretin polypeptide analogue and application thereof 北京诺尼瑞生物科技有限责任公司 2025-06-17 CN claimed
US-20250129127-A1 Systems for Amplification of AAV Rep and Cap Proteins SHAPE THERAPEUTICS INC. 2025-04-24 US claimed
CN-119823223-A Apelin peptide energy macrocycle and application thereof SOCPRA健康与人文科学有限公司 2025-04-15 CN claimed
EP-4469581-A2 SYSTEMS FOR AMPLIFICATION OF AAV REP AND CAP PROTEINS Shape Therapeutics Inc. (US) 2024-12-04 EP claimed
EP-4448547-A1 APELINERGIC MACROCYCLES AND USES THEREOF Socpra Sciences Santé Et Humaines S.E.C. (CA) 2024-10-23 EP claimed
CN-118829646-A Apelin peptide energy macrocycle and application thereof SOCPRA健康与人文科学有限公司 2024-10-22 CN claimed
US-20240343761-A1 APELINERGIC MACROCYCLES AND USES THEREOF SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) 2024-10-17 US claimed
WO-2024206577-A1 KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF RADIONETICS ONCOLOGY, INC. (US) 2024-10-03 WO claimed
WO-2005030735-A1 TRIAZINES DERIVATIVES AS CELL ADHESION INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2005-04-07 WO claimed
US-5817628-A ADMINISTERING A POLYPEPTIDE THE ROCKEFELLER UNIVERSITY (US) 1998-10-06 US claimed
US-5757408-A PRINTING IMAGE ON SUBSTRATE COATED WITH AMINO-ACID DERIVATIVE ADDITIVE; QUICK DRYING OF INK, OPTICAL DENSITY, NONCURLING XEROX CORPORATION (US) 1998-05-26 US claimed
US-5756650-A COMPOSITION COMPRISING POLYAMIC ACID, CURE ACCELERATOR SELECTED FROM GROUP CONSISTING OF NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AMINO ACID COMPOUND, AROMATIC COMPOUND HAVING TWO OR MORE HYDROXYL GROUPS KABUSHIKI KAISHA TOSHIBA (JP) 1998-05-26 US claimed
US-5683793-A Ink jet transparencies XEROX CORPORATION (US) 1997-11-04 US claimed
US-5589277-A INK JET PRINTING, AQUEOUS INKS, FAST DRYING XEROX CORPORATION (US) 1996-12-31 US claimed
EP-0667246-A1 Recording sheets containing amino acids, hydroxy acids, and polycarboxyl compounds XEROX CORPORATION (US) 1995-08-16 EP claimed
WO-1994012205-A1 DYNORPHIN A SUPPRESSION OF NATURAL KILLER CELL ACTIVITY THE ROCKEFELLER UNIVERSITY (US) 1994-06-09 WO claimed
EP-0109142-A2 Peptide and pseudopeptide derivatives IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1984-05-23 EP claimed
EP-0036713-B1 ANGIOTENSIN CONVERTING ENZYME INHIBITORS UNIVERSITY OF MIAMI (US) 1984-01-18 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240343761-A1 APELINERGIC MACROCYCLES AND USES THEREOF APLNR, AP3D1, AP3B1 BLM 768/4885SMN1; SMN2 742/4885HIF1A 4780/4885
US-20250312499-A1 KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF KISS1R, GNRHR, PROKR1 BLM 4627/4885SMN1; SMN2 3676/4885HIF1A 446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.